Veloxity Labs was founded in 2021 to redefine timelines in bioanalytical services. As an employee-owned CRO, we operate with a culture of urgency and a capacity model built for rapid, high-quality data delivery. Our team brings decades of experience—and a shared mission to move your science forward, faster.
Veloxity Labs is a bioanalytical CRO built for speed, scientific rigor and flexibility. We deliver high-quality, fast-turnaround LC-MS/MS bioanalysis to support pharmaceutical, biotech and animal health programs across discovery, preclinical and clinical development. With expertise in PK/TK, method development and regulatory compliance (GLP/GCP, ICH M10), we support both small and large molecules — including ADCs, peptides, biomarkers and plasma protein binding studies. From dried blood spots to patient-centric devices like Tasso and Mitra, our integrated microsampling capabilities set us apart. Operating under an 80% capacity model, Veloxity moves your science forward — faster. Founded in 2021 and proudly employee-owned, we bring urgency, partnership and insight to every study.
Co-Founder, President & CEO
With more than 30 years experience in bioanalysis and 200 publications, Shane is a respected industry expert. A serial entrepreneur, he has founded several businesses and CROs, which collectively have an ROI of 70,000%, and have been recognized as a fast growing company by INC 5000 and start-up of the year. Under his direction his labs have led the industry in dried blood spot analysis, microflow LC−MS/MS and small and large molecule bioanalysis. Shane sits on many company and organization boards, helping guide them in business and science-related decisions. He is often an invited speaker, TED Talk presenter, author and expert witness for analytical chemistry.
Shane holds a bachelor’s degree in chemistry from Washington State University and a PhD in chemistry from the University of Rhode Island.
Co-Founder, Laboratory Director
Prior to co-founding Veloxity Labs, Mitch held several senior-level bioanalytical and DMPK laboratory positions within the biotech and CRO industries. During that time he served as principal investigator for regulated and non-regulated preclinical studies, and developed expertise relative to method development, validation and sample analysis using LC-MS/MS and HRMS. Additionally, Mitch has experience conducting in-vitro assays, including microsomal stability and drug-drug interactions in HLM, and the quantitative analysis of small molecule test articles, metabolites, biomarkers and peptides in several biological matrices (plasma, serum, whole blood and tissues).
Mitch earned a bachelor’s degree in chemistry from Monmouth College and a PhD in analytical chemistry from the University of Missouri-Columbia.
Co-Founder, Associate Director
Colt initially began his schooling at the University of Wyoming. With the oil and gas industry so prominent in that region, he began his career determining the concentration of metals in plating baths for an electroplating facility.
He then joined Alliance Pharma where he progressed to a team lead in the bioanalytical department. While there, he gained experience multitasking in a wide variety of roles, including working on method validation and regulated sample analysis in addition to toxicology studies and early-phase clinical studies.
He used his experience and skills as a scientist to go on to co-found Veloxity Labs in 2022.
Colt received a bachelor’s degree in Chemistry from Millersville University of Pennsylvania.
Co-Founder, Executive Vice President
Paul has led an esteemed 35-year career developing lease, finance and asset management products and strategies in the pharmaceutical, biotech, clinical, healthcare and related industries. He serves as President and CEO of McKinley Scientific after co-founding the company in 2000. McKinley enjoys client relationships in over 60 countries and a clientele that ranges from the very largest pharmaceutical companies in the world to newly formed and emerging laboratories.
Additionally, Paul serves as Managing Partner of Lake Mohawk Ventures (LMV), a long-term investment and management consulting firm that brings instrumentation management and financial services to the scientific industry. LMV also supported the formation and ongoing operations of Veloxity Labs.
Co-Founder, Vice President, Procurement
Martin brings 35 years of experience around high-technology equipment sourcing, sales, service and asset management after starting his career with IBM in 1980. Over the course of his career he served in various sales and leadership roles until he joined McKinley Scientific as senior vice president of sales at its inception in 1997. Additionally, he is a business partner at Lake Mohawk Ventures (LMV), a long-term investment and management consulting company that brings instrumentation management and financial services to the scientific industry. In his role with Veloxity Labs, his sourcing and acquisition skills are used to maintain required LCMS capacity. Originally from the UK, he now calls the US his country and home.
Martin earned a BA in Business Studies at the University of Hertfordshire in the UK.
Co-Founder, Vice President, Finance
Herb has been in the equipment finance industry for over 40 years. He currently serves as president of McKinley Capital, COO and executive vice president of McKinley Scientific and vice president of finance for Veloxity Labs. Previously, he served in a variety of leadership roles for Charter Financial, Inc. (Wells Fargo Equipment Finance) until he founded Commercial Finance Group, LLC in 2003. CFG merged with McKinley Scientific in 2016.
Herb has a bachelor’s degree in business and economics from Wagner College.
Director, Biochemistry and QA
Chris brings over 25 years experience as a drug discovery biochemist, with particular expertise in compliance and regulatory bioanalysis, biomarkers and drug development. He has been involved in the development of assays for discovery and characterization of both small and macromolecules, resulting in numerous patents, publications and clinical submissions. He has worked in a variety of bioanalytical labs, developing and validating immunoassays, LC-MS/MS, cell-based, PCR and GCP-compliant DDI methods. He is a frequent speaker at SQA and other industry events.
Chris received his PhD in Experimental Medicine and Biochemistry from The University of British Columbia. Additionally, he completed post-doctorate work at McGill University and University of British Columbia.
Senior Director, BD
Callie brings more than 15 years of experience in the clinical research industry supporting pharmaceutical and medical device research and development for both human and animal health clients. During her career she has held various roles of increasing responsibility in marketing, commercial operations and sales. After earning her degree, she led the marketing activities for a large automotive dealership group. She then began her career in the CRO industry, first at Labcorp (Covance) where she supported bioanalytical, toxicology, pharmacology, drug metabolism and antibody generation services. From there she transitioned to Inotiv where she supported bioanalysis, pharmacology, toxicology and more.
Callie earned a bachelor’s degree in Business Management from North Central College.
Senior Director, BD
Shelly joined Veloxity Labs in May of 2023 where her extensive background in science and the drug development process helps her understand the challenges and needs of clients. She began her career in investigative toxicology at Eli Lilly before transitioning to Covance following their purchase of Eli Lilly’s toxicology campus, serving as a study director for non-regulated toxicology studies.
From there, she joined Seventh Wave Labs (Inotiv), serving in various business development roles and helping to shape the commercial engine as the company grew from 50 people to over 1000. She then moved to Prolytix in a business development role, supporting CMC process development and analytical services.
Shelly received her bachelor’s degree in Biology from Purdue University.
Senior Vice President
Ultragenyx
VP of Sales & Marketing
Shimadzu
Director, Bioanalytical Chemistry and DMPK
BioCryst Pharmaceuticals
Retired
Eli Lilly
President and CEO
Patel Kwan Consultancy
Vice President
Morton Community Bank
Founder
Shipley Pharma Insights
President of Discovery & Development
Insights, LLC
Bioanalytical Expert and Consultant
Drug Development Consultant
SVP of Product Development
BlueWater Bioscience
